Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience.

ABSTRACT:

SUBMITTER: Barbieri E 

PROVIDER: S-EPMC9646578 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature